Effects of Medical Treatment of Prostate Cancer on Bone Health

被引：31

作者：

Formenti, Anna Maria ^{[1
]}

Dalla Volta, Alberto ^{[2
]}

di Filippo, Luigi ^{[1
]}

Berruti, Alfredo ^{[2
]}

Giustina, Andrea ^{[1
]}

机构：

[1] San Raffaele Vita Salute Univ, San Raffaele Hosp, Inst Endocrine & Metab Sci, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy

[2] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Radiol Sci,Azienda Socio Sanit Terr ASST Spedali, Brescia, Italy

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2021年 / 32卷 / 03期

关键词：

ANDROGEN-DEPRIVATION THERAPY; GROWTH-HORMONE-SECRETION; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RANDOMIZED CONTROLLED-TRIAL; LEAN BODY-MASS; MINERAL DENSITY; VERTEBRAL FRACTURES; TRABECULAR BONE; ZOLEDRONIC ACID; DOUBLE-BLIND;

D O I：

10.1016/j.tem.2020.12.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Medical treatment of prostate cancer (PC) is multidisciplinary, resulting in prolonged survival. Androgen-deprivation therapy (ADT) can have negative effects on skeletal metabolism, particularly if combined with glucocorticoids. We discuss the pathophysiology and effects of ADT and glucocorticoids on skeletal endpoints, as well as the awareness and management of bone fragility. Coadministration of glucocorticoids is necessary with abiraterone because this causes a novel acquired form of 17-hydroxylase deficiency and synergistically increases the risk of fracture by affecting bone quality. Bone antiresorptive agents [selective estrogen receptor modulators (SERMS), bisphosphonates, and denosumab] increase bone mineral density (BMD) and in some instances reduce fracture risk in PC patients on ADT. Awareness and management of bone health in PC can be improved by integrating endocrinologists into the multidisciplinary PC team.

引用

页码：135 / 158

页数：24

共 203 条

[21]

Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]

[22] The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome [J].

Buttigliero, Consuelo ;

Vana, Federica ;

Bertaglia, Valentina ;

Vignani, Francesca ;

Fiori, Cristian ;

Osella, Giangiacomo ;

Porpiglia, Francesco ;

Tucci, Marcello ;

Scagliotti, Giorgio Vittorio ;

Berruti, Alfredo .

ENDOCRINE, 2015, 50 (01) :223-230

[23] Glucocorticoid-induced osteoporosis: pathophysiology and therapy [J].

Canalis, E. ;

Mazziotti, G. ;

Giustina, A. ;

Bilezikian, J. P. .

OSTEOPOROSIS INTERNATIONAL, 2007, 18 (10) :1319-1328

[24] Glucocorticoid-induced osteoporosis: Summary of a workshop [J].

Canalis, E ;

Giustina, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5681-5685

[25] Mechanisms of anabolic therapies for osteoporosis [J].

Canalis, Ernesto ;

Giustina, Andrea ;

Bilezikian, John P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :905-916

[26] Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors [J].

Catalano, A. ;

Gaudio, A. ;

Agostino, R. M. ;

Morabito, N. ;

Bellone, F. ;

Lasco, A. .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (11) :1337-1343

[27] Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α [J].

Cenci, S ;

Weitzmann, MN ;

Roggia, C ;

Namba, N ;

Novack, D ;

Woodring, J ;

Pacifici, R .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (10) :1229-1237

[28] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer [J].

Chi, Kim N. ;

Agarwal, Neeraj ;

Bjartell, Anders ;

Chung, Byung Ha ;

Pereira de Santana Gomes, Andrea J. ;

Given, Robert ;

Juarez Soto, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Deprince, Kris ;

Naini, Vahid ;

Li, Jinhui ;

Cheng, Shinta ;

Yu, Margaret K. ;

Zhang, Ke ;

Larsen, Julie S. ;

McCarthy, Sharon ;

Chowdhury, Simon .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) :13-24

[29] Treatment options for glucocorticoid-induced osteoporosis [J].

Chiodini, Iacopo ;

Merlotti, Daniela ;

Falchetti, Alberto ;

Gennari, Luigi .

EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) :721-732

[30] Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy [J].

Choo, Richard ;

Lukka, Himu ;

Cheung, Patrick ;

Corbett, Tom ;

Briones-Urbina, Rosario ;

Vieth, Reinhold ;

Ehrlich, Lisa ;

Kiss, Alex ;

Danjoux, Cyril .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (05) :1239-1245

← 1 2 3 4 5 6 7 8 9 10 →